<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-03-01</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-03-01</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>61</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
CAR-Macrophageç–—æ³•é€šè¿‡é‡å¡‘è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒå±•ç°æŠ—è‚¿ç˜¤æ½œåŠ›ï¼›ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºå‘è‚²ä¸­è‚è„å¾®ç¯å¢ƒçš„å•ç»†èƒåˆ†è¾¨ç‡ç‰¹å¾ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å…ç–«æ²»ç–—ï¼šCAR-Macrophageã€CAR-Tç»†èƒç­–ç•¥ã€LAG3é¶å‘IL-2ã€Nrf2/Keap1é€šè·¯è°ƒæ§ã€‚<br />
- è‚¿ç˜¤å¾®ç¯å¢ƒä¸è€è¯æœºåˆ¶ï¼šGABAå¯¹å…ç–«æ²»ç–—æŠµæŠ—çš„å½±å“ã€RBX1ä¿ƒè¿›è‚¾ç™Œä¾µè¢­ä¸è€è¯ã€è‚¿ç˜¤è¥å…»å‹åŠ›è¯±å¯¼çš„è€è¯çŠ¶æ€ã€FGFBP2åœ¨èƒ°è…ºç™Œè¿›å±•ä¸­çš„ä½œç”¨ã€‚<br />
- ç»†èƒä»£è°¢ä¸ç–¾ç—…ï¼šé…®é¥®é£Ÿå¯¹èƒ°è…ºç™Œçš„æ•æ„ŸåŒ–ã€çº¿ç²’ä½“ROSè°ƒæ§ä¸åŒ–ç–—è€è¯ã€ä¹³é…¸ä¸ç»„è›‹ç™½ä¿®é¥°åœ¨è§†ç½‘è†œä¸­çš„ä½œç”¨ã€Lisinoprilå¯¹ALSçš„æ½œåœ¨æ²»ç–—ç­–ç•¥ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å¤šæ¨¡æ€ç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯åº”ç”¨äºå‘è‚²ç”Ÿç‰©å­¦ç ”ç©¶ã€‚<br />
- scRNA-seqä¸scATAC-seqè”åˆåº”ç”¨äºè¡€ç®¡å¹³æ»‘è‚Œç»†èƒçŠ¶æ€è½¨è¿¹ç ”ç©¶ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç§‘å­¦å®¶å‘ç°æ‰“ç ´é—ä¼ å¯†ç åŸºæœ¬è§„åˆ™çš„å¾®ç”Ÿç‰©ï¼›ç¾å›½å¿ƒè„åä¼šé¢„è­¦å¥³æ€§å¿ƒè¡€ç®¡ç–¾ç—…é£é™©æ¿€å¢ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- å•ç»†èƒå¤šæ¨¡æ€æµ‹åºæŠ€æœ¯ï¼ˆæŸ“è‰²è´¨å¯åŠæ€§ä¸åŸºå› è¡¨è¾¾ï¼‰<br />
- RNAæµ‹åºæ•°æ®åˆ†æçš„è‡ªåŠ¨åŒ–ä¸ç®€åŒ–<br />
- å¥³æ€§å¿ƒè¡€ç®¡ç–¾ç—…å‘ç—…ç‡é¢„æµ‹<br />
- å¾®ç”Ÿç‰©é—ä¼ å¯†ç ç ”ç©¶</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- SUM-seqï¼šå®ç°å•ç»†èƒè¶…é«˜é€šé‡å¤šé‡æŸ“è‰²è´¨å¯åŠæ€§ä¸åŸºå› è¡¨è¾¾æµ‹åºã€‚<br />
- REDACï¼šé€šè¿‡è‡ªç„¶è¯­è¨€æŸ¥è¯¢ç®€åŒ–RNAæµ‹åºæ•°æ®åˆ†ææµç¨‹ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (57æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE275837 åµŒåˆæŠ—åŸå—ä½“-å·¨å™¬ç»†èƒå¤–å›Šæ³¡é‡ç¼–ç¨‹å…ç–«å¾®ç¯å¢ƒç”¨äºç™Œç—‡æ²»ç–— [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€macrophageã€antigenã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Minghe Zhang ; Peng Xia ; Yufeng YuanSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmunotherapy has become a new milestone in cancer treatment, with chimeric antigen receptor (CAR)-T cell therapy proven to be an effective method for treating hematologic malignancies. However, its efficacy in solid tumors remains limited. Macrophages, the most infiltrative innate immune cells in the tumor microenvironment, are being genetically engineered to express CARs, rapidly emerging as a promising new therapy for non-hematologic malignancies. Yet, CAR- Macrophages therapy is associated with unique acute toxicities and is susceptible to immunosuppressive mechanisms. Here, we propose using CAR macrophages-derived extracellular vesicles (CAR-MEVs) as an optimization of CAR-Ms therapy. Compared to CAR-Ms cells, CAR-MEVs exhibit lower toxicity and enhanced drug delivery capabilities. In an in vivo liver cancer model, CAR-MEVs administration proved safer than CAR-Ms therapy, reducing tumor burden and prolonging overall survival. In a humanized mouse model, CAR-MEVs further demonstrated the ability to induce a pro-inflammatory tumor microenvironment and enhance anti-tumor T cell activity. Mechanistically, CAR-MEVs target tumor cells, inducing immunogenic cell death (ICD) and subsequently leading to neutrophil infiltration in tumor tissues. We demonstrated that the anti-tumor effects of CAR-MEVs depend on neutrophils and are partially reliant on inducible nitric oxide synthase (iNOS). This study supports the potential of macrophage extracellular vesicles as a novel therapeutic approach for solid tumors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275837" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE273952 GABA ä¿ƒè¿› TLS é˜³æ€§è‚¿ç˜¤æ‚£è€…å¯¹å…ç–«ç–—æ³•çš„è€è¯æ€§ [ç©ºé—´è½¬å½•ç»„å­¦]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šregex:immuno(logy|therapy|suppression)ã€resistanceã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Isaias Hernandez-Verdin ; Anne Calvez ; Antoine BougoÃ¼in ; Cheng-Ming Sun ; Asmat Ullah ; Virgine Verkarre ; Yann-Alexandre Vano ; Lucile Vanhersecke ; Alban Bessede ; Jean-Philippe Guegan ; Antoine Italiano ; StÃ©phane Oudard ; Catherine SautÃ¨s-Fridman ; Wolf H FridmanSeries Type : OtherOrganism : Homo sapiensTertiary lymphoid structures (TLS) in the tumour microenvironment have been linked to positive clinical outcomes and responses to immune checkpoint inhibitors (ICI) in various cancers, including clear cell renal cell carcinoma (ccRCC) and soft tissue sarcoma (STS). However, a significant proportion of patients do not respond to ICI despite the presence of TLS. Our study unravels gamma-aminobutyric acid (GABA), a neurotransmission inhibitor, as a modulator of ICI resistance in TLS-positive tumours. By leveraging household and public multi-omic data, we demonstrated that GABA is upregulated in TLS-positive ccRCC and STS tumours from non-responders to ICI. In metastatic ccRCC, TLS from non-responders were distinguished from responders by a dysfunctional immune activation and a close proximity to GABA-producing proximal tubule-like tumour cells. The addition of a competitive inhibitor of GABA synthesis, 3-mercaptopropionic acid, significantly improved tumour control when compared to anti-PD1 alone when intra-tumourally injected in a mouse model of STS. Overall, our findings highlight GABA as a novel determinant of non-response to ICI in tumours harboring TLS, suggesting potential new approaches for patient stratification and personalized therapeutic strategies that could be applicable beyond metastatic ccRCC and STS.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273952" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE306606 å¤šæ¨¡æ€ç©ºé—´è½¬å½•ç»„å­¦ä»¥å•ç»†èƒåˆ†è¾¨ç‡æ­ç¤ºäººç±»è‚è„å‘è‚²å¾®ç¯å¢ƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cellã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Carolyn SangokoyaSeries Type : OtherOrganism : Homo sapiensA comprehensive understanding of the fetal liver niche during development offers a lens into a unique natural multifunctional multicellular environment. Here we use a spatial transcriptomic and histologic analysis approach to identify and histologically confirm RNA-based markers in human fetal liver tissue within a key developmental window in which the liver is a major site of hematopoiesis, just prior to the increased growth phase of the final trimester. Within this window, the fetal liver niche encompasses the unique coexistence of cells of both endodermal and mesenchymal origin with the unique environment fostering hematopoietic cell development as well as hepatocyte function. Single-cell resolution spatial imaging reveals epithelial, hematopoietic, endothelial, and stromal cell populations in shared cellular microenvironments. Here, our single-cell spatial transcriptomic and imaging approach enables, captures, and confirms the complex phenomena of ductal plate expression and CXCL12 homing to the hematopoietic stem cell niche (HSC) in the liver. An RNA-based understanding of the functional diversity and in situ spatial organization of the fetal liver niche is critical for adequate validation and authentication in recapitulating and re-engineering these regenerative environments in vitro.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306606" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE318757 SynNotch-iNOS CAR-å·¨å™¬ç»†èƒé‡å¡‘è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒï¼Œå¹¶é€šè¿‡CD4+ Tç»†èƒä¾èµ–æ€§æœºåˆ¶å‘æŒ¥æŠ—è‚¿ç˜¤åŠŸæ•ˆ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immuneã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yuling Hong ; Buyun Dang ; Shih-Chin ChengSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusBackground: Chimeric antigen receptor T-cell (CAR-T) therapy shows limited efficacy against solid tumors due to the immunosuppressive tumor microenvironment (TIME). Macrophages possess superior infiltration capabilities, yet their therapeutic potential remains under-realized. Methods: We engineered a synNotch-iNOS CAR-macrophage (CAR iNOS-M) that releases nitric oxide (NO) upon CD19 recognition. Its efficacy was evaluated in syngeneic, immunocompetent murine models of metastatic melanoma. Results: CAR iNOS-M therapy effectively reprogrammed the pulmonary TIME, inducing potent antitumor responses independent of CD8+ T cells but strictly dependent on CD4+ T cells. Mechanistically, CAR iNOS-M treatment led to a significant reduction in pro-tumorigenic lung interstitial macrophages (IMs), subsequently decreasing platelet factor 4 (PF4) levels. This disruption of the PF4 signaling axis inhibited the polarization of immunosuppressive Th1-Tregs, alleviating T-cell exhaustion. Conclusions: This study delineates a novel indirect mechanism for CAR-M, shifting the focus from direct phagocytosis to strategic TIME remodeling, providing a foundation for treating solid tumors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318757" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE318979 åˆ©ç”¨ LAG3 é¶å‘çš„ç™½ç»†èƒä»‹ç´ -2 é¶å‘è‚¿ç˜¤ç‰¹å¼‚æ€§ T ç»†èƒå¯é˜²æ­¢ T ç»†èƒè€—ç«­å¹¶é‡æ–°æ¿€æ´»æŠ—è‚¿ç˜¤å…ç–«åŠ›</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiaohong Yu ; Huiping LiaoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusLAG3 is a critical inhibitory receptor that is highly enriched on exhausted T cells within the tumor microenvironment (TME), where it functions as a key driver of T cell exhaustion-an archetypal barrier to robust antitumor immunity. In a colon cancer model, we identified that LAG3+CD8+ tumor-infiltrating lymphocytes (TILs) constitute the predominant tumor-specific T cells but exhibit defective IL2 signaling. To address whether exogenous IL2 replenishment unpins their dysfunction, we engineered LAG3-LaIL2 (low-affinity IL2), a fusion protein delivering IL2 selectively to LAG3+CD8+ TILs. LAG3-LaIL2 expanded pre-exhausted tumor-specific CD8+ T cells, reprogrammed their exhaustion trajectory toward an intermediate effector state, and prevented terminal exhaustion, leading to tumor regression and prolonged survival in mice. Mechanistically, LAG3-LaIL2 restored IL2R-JAK3-STAT5 signaling by upregulating the high-affinity IL2 receptor subunit CD122, thereby rejuvenating TIL functionality. Furthermore, LAG3-LaIL2 amplified tumor-specific effector and memory T cells in draining lymph nodes, enabling systemic antitumor immunity against distal tumors and preventing tumor recurrence. Collectively, our findings validate LAG3-LaIL2 as a precision immunotherapeutic agent that specifically targets exhausted TILs, concomitantly enhancing therapeutic efficacy and safety by restricting IL2 exposure to non-target cells. This strategy provides a translatable approach to overcoming T cell exhaustion in solid tumors, offering a promising avenue to improve clinical outcomes for cancer patients<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318979" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE304059ï¼šRBX1ä¿ƒè¿›è‚¾é€æ˜ç»†èƒç™Œä¾µè¢­ã€å…ç–«æŠ‘åˆ¶å’Œèˆ’å°¼æ›¿å°¼è€è¯çš„æœºåˆ¶ç ”ç©¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€immuneã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yi Yu ; shaochao Zhan ; Yuchen Li ; Zhaohui Guo ; Ting Li ; Chengjian Xie ; Tao YangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensClear cell renal cell carcinoma (ccRCC) often exhibits drug resistance, highlight_x0002_ing the need to identify novel therapeutic targets. RING box protein 1 (RBX1), an E3 ubiquitin ligase associated with tumor progression, has an unclear role in ccRCC. This study investigated the clinical significance, molecular mech_x0002_anisms, and role of RBX1 in treatment resistance through multi-omics and functional analyses. Analysis of The Cancer Genome Atlas (TCGA) data revealed that RBX1 is overexpressed in ccRCC and is associated with advanced dis_x0002_ease stages and poor prognosis. Functional enrichment studies linked RBX1 to processes such as cytoskeletal remodeling,extracellular matrix deposition, and lipid metabolism disorders.Additionally, tumors with high RBX1 expression exhibit an immunosuppressive microenvironment characterized by increased reg_x0002_ulatory T cells (Tregs) and elevated expression of immune checkpoint markers (LAG3/Galectin-9). In vitro experiments confirmed that RBX1 promotes ccRCC proliferation, migration, and invasion while conferring resistance to the standard targeted therapy drug sunitinib. Our findings suggest that RBX1 may serve as a key driver of ccRCC invasiveness and immune suppression. These discoveries indicate that RBX1 has the potential to become a prognostic biomarker and a target for precision therapy in advanced ccRCC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304059" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE282444 ç‚ç—‡æ€§è‚ ç—…ä¸­è‚ ä¸Šçš®ç»†èƒçš„è¡¨è§‚é—ä¼ è®°å¿† [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€epigeneticã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Brooke R Druliner ; Feda HamdanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe pathogenesis of Inflammatory Bowel Disease (IBD) is a multifactorial process characterized by inflammation and damage to the intestinal barrier, which is made up of intestinal epithelial cells (IECs). Since IBD is a remitting and relapsing disease, we postulated that epigenetic memory exists in IECs following an inflammatory encounter. The objective of this study was to uncover the mechanisms of a retained altered IEC epigenetic landscape in the context of IBD. We have generated adult stem cell organoids (containing all epithelial cell lineages) from patients with Ulcerative Colitis (UC); two organoid lines per patient were propagated: 1) from a site of active inflammation and from the same patient, and 2) a never inflamed region. We performed Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) and bulk RNA-seq on each organoid line. Established bioinformatic pipelines were used to determine significantly different chromatin accessibility and differentially expressed genes. Functional significance of the open chromatin regions was assessed by pathway and motif analysis. Treatment with TNF-alpha (10 and 100ng/ml) for 24 hours on the organoids was performed to determine re-activation of pro-inflammatory genes. This study shows for the first time that epithelial cells derived from organoids of IBD patients retain an epigenetic memory of the prior inflammatory state.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282444" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE282442 ç‚ç—‡æ€§è‚ ç—…ä¸­è‚ ä¸Šçš®ç»†èƒçš„è¡¨è§‚é—ä¼ è®°å¿† [ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šATAC-seqã€epigeneticã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Brooke R Druliner ; Feda HamdanSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe pathogenesis of Inflammatory Bowel Disease (IBD) is a multifactorial process characterized by inflammation and damage to the intestinal barrier, which is made up of intestinal epithelial cells (IECs). Since IBD is a remitting and relapsing disease, we postulated that epigenetic memory exists in IECs following an inflammatory encounter. The objective of this study was to uncover the mechanisms of a retained altered IEC epigenetic landscape in the context of IBD. We have generated adult stem cell organoids (containing all epithelial cell lineages) from patients with Ulcerative Colitis (UC); two organoid lines per patient were propagated: 1) from a site of active inflammation and from the same patient, and 2) a never inflamed region. We performed Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) and bulk RNA-seq on each organoid line. Established bioinformatic pipelines were used to determine significantly different chromatin accessibility and differentially expressed genes. Functional significance of the open chromatin regions was assessed by pathway and motif analysis. Treatment with TNF-alpha (10 and 100ng/ml) for 24 hours on the organoids was performed to determine re-activation of pro-inflammatory genes. This study shows for the first time that epithelial cells derived from organoids of IBD patients retain an epigenetic memory of the prior inflammatory state.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282442" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE273829 GABA ä¿ƒè¿› TLS é˜³æ€§è‚¿ç˜¤æ‚£è€…å¯¹å…ç–«ç–—æ³•çš„è€è¯æ€§ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šregex:immuno(logy|therapy|suppression)ã€resistanceã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Isaias Hernandez-Verdin ; Anne Calvez ; Antoine BougoÃ¼in ; Cheng-Ming Sun ; Asmat Ullah ; Virgine Verkarre ; Yann-Alexandre Vano ; Lucile Vanhersecke ; Alban Bessede ; Jean-Philippe Guegan ; Antoine Italiano ; StÃ©phane Oudard ; Catherine SautÃ¨s-Fridman ; Wolf H FridmanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTertiary lymphoid structures (TLS) in the tumour microenvironment have been linked to positive clinical outcomes and responses to immune checkpoint inhibitors (ICI) in various cancers, including clear cell renal cell carcinoma (ccRCC) and soft tissue sarcoma (STS). However, a significant proportion of patients do not respond to ICI despite the presence of TLS. Our study unravels gamma-aminobutyric acid (GABA), a neurotransmission inhibitor, as a modulator of ICI resistance in TLS-positive tumours. By leveraging household and public multi-omic data, we demonstrated that GABA is upregulated in TLS-positive ccRCC and STS tumours from non-responders to ICI. In metastatic ccRCC, TLS from non-responders were distinguished from responders by a dysfunctional immune activation and a close proximity to GABA-producing proximal tubule-like tumour cells. The addition of a competitive inhibitor of GABA synthesis, 3-mercaptopropionic acid, significantly improved tumour control when compared to anti-PD1 alone when intra-tumourally injected in a mouse model of STS. Overall, our findings highlight GABA as a novel determinant of non-response to ICI in tumours harboring TLS, suggesting potential new approaches for patient stratification and personalized therapeutic strategies that could be applicable beyond metastatic ccRCC and STS.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273829" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE321762 è¡€ç®¡å¹³æ»‘è‚Œç»†èƒçŠ¶æ€è½¨è¿¹ä»‹å¯¼å† å¿ƒç—…é£é™©çš„åˆ†å­æœºåˆ¶[scRNA-seq å’Œ scATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šscRNAã€scATAC<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Daniel Y Li ; Thomas QuertermousSeries Type : Genome binding/occupancy profiling by high throughput sequencing ; Expression profiling by high throughput sequencingOrganism : Mus musculusVascular smooth muscle cells contribute to heritable coronary artery disease risk and undergo complex transitions to multiple disease-related phenotypes. To investigate the genetic basis of these trajectories, we develop a dense timecourse single cell transcriptomic and epigenetic map of atherosclerosis in a murine disease model accompanied by high-plex in situ spatial data. Using temporal data and probabilistic fate modeling, we identify key transcription factors that drive cell state changes through a combination of network-based prioritization and in silico transcription factor perturbation. Parallel knockout studies of validated coronary artery disease gene Tcf21 uncover its molecular mechanisms in smooth muscle cell transition, due in part to a role regulating the transition of smooth muscle cells in the secondary heart field. Integrating the murine atlas with human coronary artery disease genetics pinpoint smooth muscle cell phenotypes that mediate disease risk, highlighting causal disease mechanisms. Together, these studies resolve atherosclerosis trajectories at single cell resolution and identify genetic causal transcriptomic and epigenomic mechanisms of coronary artery disease risk.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE321762" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 47 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>SUM-seqâ€”â€”å•ç»†èƒè¶…é«˜é€šé‡å¤šé‡æŸ“è‰²è´¨å¯åŠæ€§å’ŒåŸºå› è¡¨è¾¾æµ‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSUM-seq enables scalable single cell chromatin accessibility and RNA sequencing, supporting high throughput multimodal profiling for large atlas projects and regulatory network analysis...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/sum-seq-single-cell-ultra-high-throughput-multiplexed-chromatin-accessibility-and-gene-expression-sequencing/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>èŠå¤©æœºå™¨äººç®€åŒ–äº†RNAæµ‹åºæ•°æ®åˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šREDAC enables accessible RNA sequencing expression analysis through natural language queries, automated normalization and differential testing, and AI guided pathway...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/a-chatbot-simplifies-rna-sequencing-data-analysis/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ç¾å›½å¿ƒè„åä¼šè­¦å‘Šç§°ï¼Œåˆ°2050å¹´ï¼Œ60%çš„ç¾å›½å¥³æ€§å°†æ‚£æœ‰å¿ƒè¡€ç®¡ç–¾ç—…ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcardiovascular<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šHeart disease is on track to tighten its grip on American women. New projections from the American Heart Association warn that over the next 25 years, cardiovascular disease will rise sharply, driven largely by a surge in high blood pressure, diabetes, and obesity. By 2050, nearly 60% of women in the U.S. could have high blood pressure, and close to one in three women ages 22 to 44 may already be living with some form of heart disease.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260227061818.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>ç§‘å­¦å®¶å‘ç°ä¸€ç§å¾®ç”Ÿç‰©ï¼Œå®ƒæ‰“ç ´äº†é—ä¼ å¯†ç çš„ä¸€æ¡åŸºæœ¬è§„åˆ™ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šregex:micro(b|be|bial|organism)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists at UC Berkeley have discovered a microbe that bends one of biologyâ€™s most sacred rules. Instead of treating a specific three-letter DNA code as a clear â€œstopâ€ signal, this methane-producing archaeon sometimes reads it as a green lightâ€”adding an unusual amino acid and continuing to build the protein. The result is a kind of genetic coin flip: two different proteins can emerge from the same code, influenced partly by environmental conditions.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260227071920.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>11</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>8</td>
</tr>
<tr>
<td>metabolic</td>
<td>8</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>6</td>
</tr>
<tr>
<td>tumor</td>
<td>5</td>
</tr>
<tr>
<td>sequencing</td>
<td>4</td>
</tr>
<tr>
<td>T cell</td>
<td>4</td>
</tr>
<tr>
<td>resistance</td>
<td>4</td>
</tr>
<tr>
<td>single-cell</td>
<td>3</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>scRNA</td>
<td>3</td>
</tr>
<tr>
<td>transcriptome</td>
<td>3</td>
</tr>
<tr>
<td>inflammation</td>
<td>3</td>
</tr>
<tr>
<td>macrophage</td>
<td>2</td>
</tr>
<tr>
<td>metabolism</td>
<td>2</td>
</tr>
<tr>
<td>spatial</td>
<td>2</td>
</tr>
<tr>
<td>spatial transcriptomics</td>
<td>2</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>2</td>
</tr>
<tr>
<td>KRAS</td>
<td>2</td>
</tr>
<tr>
<td>carcinoma</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (47æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320214" target="_blank" rel="noopener noreferrer">GSE320214 ç”Ÿé…®é¥®é£Ÿä½¿èƒ°è…ºç™Œå¯¹è°·æ°¨é…°èƒºä»£è°¢æŠ‘åˆ¶å‰‚æ›´æ•æ„Ÿ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314386" target="_blank" rel="noopener noreferrer">GSE314386 C15ORF48 å¯¹åŸºåº•ç»†èƒäºšç¾¤ä¸­çº¿ç²’ä½“ ROS çš„è°ƒæ§å¯¼è‡´ä¸‰é˜´æ€§ä¹³è…ºç™ŒåŒ–ç–—è€è¯</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE322475" target="_blank" rel="noopener noreferrer">GSE322475 ä¹³é…¸å’Œç»„è›‹ç™½ H3K18 ä¹³é…¸åŒ–ä¸è§†ç½‘è†œåŸºå› è¡¨è¾¾çš„ä»£è°¢æ§åˆ¶ç›¸å…³ [explant_RNA-seq 2]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320331" target="_blank" rel="noopener noreferrer">GSE320331 è‚¿ç˜¤è¥å…»åº”æ¿€å¯¼è‡´èƒ°è…ºç™Œç»†èƒäº§ç”Ÿè€è¯çŠ¶æ€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318648" target="_blank" rel="noopener noreferrer">GSE318648 ç ”ç©¶å‘ç°ï¼Œè‚¿ç˜¤ç›¸å…³æˆçº¤ç»´ç»†èƒä¸­çš„ FGFBP2 p.T186S çªå˜é€šè¿‡è‡ªåˆ†æ³Œå’Œæ—åˆ†æ³Œæœºåˆ¶ä¿ƒè¿›èƒ°è…ºç™Œçš„è¿›å±•ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318425" target="_blank" rel="noopener noreferrer">GSE318425 æ…¢æ€§ç‚ç—‡é€šè¿‡ADAM10ä»‹å¯¼çš„CX3CL1è£‚è§£ä¿ƒè¿›èƒƒç™Œè¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316853" target="_blank" rel="noopener noreferrer">GSE316853 N-ä¹™é…°åŠèƒ±æ°¨é…¸å¯¹Nrf2/Keap1é€šè·¯è°ƒæ§ï¼šé¢„é˜²å®éªŒæ€§è‚ç»†èƒç™Œçš„å…³é”®æœºåˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315444" target="_blank" rel="noopener noreferrer">GSE315444 é¹…èƒ¸è…ºå•ç»†èƒåˆ†ææ­ç¤ºTç»†èƒåˆ†åŒ–çš„å‘è‚²ç¨‹åºå’Œè°ƒæ§é€»è¾‘</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285080" target="_blank" rel="noopener noreferrer">GSE285080 HDAC5 ç¼ºå¤±ä¿ƒè¿› FOXA1 è¿‡åº¦ä¹™é…°åŒ–å¹¶å¢å¼ºèƒ°è…ºç™Œä¸­ HIF1Î± è½¬å½•æ¿€æ´» [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316495" target="_blank" rel="noopener noreferrer">GSE316495 p300/CREBBPå‚¬åŒ–æ´»æ€§çš„æŠ‘åˆ¶é©±åŠ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…ï¼ˆAMLï¼‰ä¸­ä¾èµ–äºä¸Šä¸‹æ–‡çš„è½¬å½•æ¿€æ´»ã€‚[ChIP-Seq 2]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304612" target="_blank" rel="noopener noreferrer">GSE304612 p300/CREBBPå‚¬åŒ–æ´»æ€§çš„æŠ‘åˆ¶é©±åŠ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…ï¼ˆAMLï¼‰ä¸­ä¾èµ–äºä¸Šä¸‹æ–‡çš„è½¬å½•æ¿€æ´»ã€‚[ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304493" target="_blank" rel="noopener noreferrer">GSE304493 p300/CREBBPå‚¬åŒ–æ´»æ€§çš„æŠ‘åˆ¶é©±åŠ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…ï¼ˆAMLï¼‰ä¸­ä¾èµ–äºç‰¹å®šç¯å¢ƒçš„è½¬å½•æ¿€æ´»ã€‚[RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303021" target="_blank" rel="noopener noreferrer">GSE303021 Hdac11é€šè¿‡æŠ‘åˆ¶Parkinä¾èµ–æ€§çº¿ç²’ä½“è‡ªå™¬ï¼Œä¿ƒè¿›å·¨å™¬ç»†èƒM2å‹æåŒ–å’Œè‚Œæˆçº¤ç»´ç»†èƒåˆ†åŒ–ï¼Œä»è€Œä¿ƒè¿›ç‰¹å‘æ€§è‚ºçº¤ç»´åŒ–ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301454" target="_blank" rel="noopener noreferrer">GSE301454 èµ–è¯ºæ™®åˆ©æ¿€æ´»BI1é‡ç¼–ç¨‹è„‚è´¨ä»£è°¢å¹¶æ¢å¤è‡ªå™¬ï¼šæ¢ç´¢ALSçš„æ–°æ²»ç–—ç­–ç•¥</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279644" target="_blank" rel="noopener noreferrer">GSE279644 BCR::ABL1 è¯±å¯¼çš„å¢å¼ºå­é‡ç¼–ç¨‹æ­ç¤º Ph+B-ALL ç»†èƒå¯¹é¶å‘å¢å¼ºå­çš„è¯ç‰©çš„è¶…æ•æ€§ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279594" target="_blank" rel="noopener noreferrer">GSE279594 BCR::ABL1 è¯±å¯¼çš„å¢å¼ºå­é‡ç¼–ç¨‹æ­ç¤º Ph+B-ALL ç»†èƒå¯¹å¢å¼ºå­é¶å‘è¯ç‰©çš„è¶…æ•ååº” [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230361" target="_blank" rel="noopener noreferrer">GSE230361 ç”¨åœŸæ‹‰éœ‰ç´ è¿›è¡Œé¢„é˜²æ€§æ²»ç–—çš„ç‰›çš„å…¨è¡€ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318685" target="_blank" rel="noopener noreferrer">GSE318685 IL6 ç¼ºå¤±å¯¹ Arid1a/Pik3ca å…±çªå˜å°é¼ åµå·¢è‚¿ç˜¤ç»†èƒç³»åŸºå› è¡¨è¾¾çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303383" target="_blank" rel="noopener noreferrer">GSE303383 é«˜è„‚é¥®é£Ÿè¯±å¯¼çš„ä»£è°¢ç»¼åˆå¾ç”± JNK7b åŒå·¥å‹ä¿ƒè¿›</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302874" target="_blank" rel="noopener noreferrer">GSE302874 é«˜è„‚é¥®é£Ÿè¯±å‘çš„ä»£è°¢ç»¼åˆå¾æ˜¯ç”± JNK7b åŒå·¥å‹ä¿ƒè¿›çš„ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297857" target="_blank" rel="noopener noreferrer">GSE297857 é«˜è„‚é¥®é£Ÿè¯±å¯¼çš„ä»£è°¢ç»¼åˆå¾ç”± JNK7b åŒå·¥å‹ä¿ƒè¿›</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243452" target="_blank" rel="noopener noreferrer">GSE243452 Effete å’Œ Cullin 4 å½±å“å‰æ™®èµ›æŸ“è‰²è´¨ç»ç¼˜å­çš„æ ¸ç»„ç»‡ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243451" target="_blank" rel="noopener noreferrer">GSE243451 Effete å’Œ Cullin 4 å½±å“å‰æ™®èµ›æŸ“è‰²è´¨ç»ç¼˜å­çš„æ ¸ç»„ç»‡ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317990" target="_blank" rel="noopener noreferrer">GSE317990 ç¿»è¯‘å› å­ eIF4G2 é€šè¿‡é€‰æ‹©æ€§åœ°æ¿€æ´» IL-7 å—ä½“ååº”æ¥æŒ‡å¯¼ CD8âº T ç»†èƒè°±ç³»åˆ†åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281332" target="_blank" rel="noopener noreferrer">GSE281332 é«˜è„‚é¥®é£Ÿè¯±å¯¼çš„ä»£è°¢ç»¼åˆå¾ç”± JNK7b åŒå·¥å‹ä¿ƒè¿› [inguinalfat_J1J2Liv_RNAseq1]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278155" target="_blank" rel="noopener noreferrer">GSE278155 é«˜è„‚é¥®é£Ÿè¯±å¯¼çš„ä»£è°¢ç»¼åˆå¾ç”± JNK7b åŒå·¥å‹ä¿ƒè¿› [Liver_RNAseq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277336" target="_blank" rel="noopener noreferrer">GSE277336 é«˜è„‚é¥®é£Ÿè¯±å¯¼çš„ä»£è°¢ç»¼åˆå¾ç”± JNK7b åŒå·¥å‹ä¿ƒè¿›</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320297" target="_blank" rel="noopener noreferrer">GSE320297 è±èŒµè¡£è—» CreTPT10 çªå˜ä½“åœ¨å‘å»¶é•¿é»‘æš—è¿‡æ¸¡æœŸé—´çš„è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320268" target="_blank" rel="noopener noreferrer">GSE320268 KRAS G12C çªå˜æ‚£è€…åŸºçº¿ç»„ç»‡æ ·æœ¬çš„è¡¨è¾¾åˆ†æä»¥åŠ KRAS G12C æŠ‘åˆ¶å‰‚æ²»ç–—æœŸé—´çš„çºµå‘è¡€æ¶²ç›‘æµ‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320266" target="_blank" rel="noopener noreferrer">GSE320266 KRAS G12C çªå˜æ‚£è€…æ¥å— KRAS G12C æŠ‘åˆ¶å‰‚æ²»ç–—æœŸé—´è¡€æµ†æ ·æœ¬çš„è¡¨è¾¾åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317876" target="_blank" rel="noopener noreferrer">GSE317876 é’è’¿ç´  (ATT) çš„å¤šé˜¶æ®µè½¬å½•ç»„èµ„æºï¼Œç”¨äºå¢å¼ºè‚è„ç±»å™¨å®˜åŠŸèƒ½å’Œæ²»ç–—ä»£è°¢æ€§è‚ç—…ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314202" target="_blank" rel="noopener noreferrer">GSE314202 è±å½¢è›‹ç™½é…¶RHBDL4çš„ç¼ºå¤±ä¼šå»¶ç¼“ä¹³è…ºç™Œå°é¼ æ¨¡å‹ä¸­è‚¿ç˜¤çš„å‘ç”Ÿ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313460" target="_blank" rel="noopener noreferrer">GSE313460 æ¤ç‰©åŠä¹³ç³–è„‚å¯¹è€è¯æ€§ç»“ç›´è‚ ç™Œçš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312390" target="_blank" rel="noopener noreferrer">GSE312390 Cç«¯é—­åˆè›‹ç™½è‚½é€šè¿‡ä¿®å¤å±éšœæŠ‘åˆ¶æ°”é“ç‚ç—‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307350" target="_blank" rel="noopener noreferrer">GSE307350 SKI å¯¹è¿œç«¯æŠ‘åˆ¶å…ƒä»¶ä¸Šèƒšèƒç è›‹ç™½åŸºå› çš„è½¬å½•æŠ‘åˆ¶ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307347" target="_blank" rel="noopener noreferrer">GSE307347 SKI å¯¹è¿œç«¯æŠ‘åˆ¶å…ƒä»¶ä¸Šèƒšèƒç è›‹ç™½åŸºå› çš„è½¬å½•æŠ‘åˆ¶ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302600" target="_blank" rel="noopener noreferrer">GSE302600 RNAç»“åˆè›‹ç™½Zfp697è°ƒæ§è‚è„ç‚ç—‡ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290016" target="_blank" rel="noopener noreferrer">GSE290016ï¼šæ©æ‰å¢èƒºæ•æ„Ÿå’Œè€è¯çš„CWR-R1ã€C4-2Bå’ŒVCaPç»†èƒçš„è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289910" target="_blank" rel="noopener noreferrer">GSE289910 è½¬å½•ç»„åˆ†æAHRæ•²ä½å¯¹æ©æ‰å¢èƒºè€è¯çš„CWR-R1å’ŒC4-2Bç»†èƒçš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289313" target="_blank" rel="noopener noreferrer">GSE289313 AHRåœ¨ä»‹å¯¼å‰åˆ—è…ºç™Œå¯¹æ©æ‰å¢èƒºçš„ä¸åŒååº”ä¸­å‘æŒ¥é‡è¦ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288895" target="_blank" rel="noopener noreferrer">GSE288895 æ–°ä¸€ä»£æµ‹åºæŠ€æœ¯ä¿ƒè¿›äº†HAECWTå’ŒHAECSAHH-KOçš„å®šé‡åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274244" target="_blank" rel="noopener noreferrer">GSE274244 Arx åœ¨å‘è‚²ä¸­çš„ä¸­é—´ç¥ç»å…ƒä¸­çš„ä½œç”¨ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274243" target="_blank" rel="noopener noreferrer">GSE274243 Arx åœ¨å‘è‚²ä¸­çš„ä¸­é—´ç¥ç»å…ƒä¸­çš„ä½œç”¨ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263573" target="_blank" rel="noopener noreferrer">GSE263573 HDAC5 ç¼ºå¤±ä¿ƒè¿› FOXA1 è¿‡åº¦ä¹™é…°åŒ–å¹¶å¢å¼ºèƒ°è…ºç™Œä¸­ HIF1Î± çš„è½¬å½•æ¿€æ´»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE260513" target="_blank" rel="noopener noreferrer">GSE260513 æ¢ç´¢åŒç›¸æƒ…æ„Ÿéšœç¢ä¸­PDE5Açš„ä¸Šè°ƒï¼šæ¥è‡ªäººç±»åŸºåº•ç¥ç»èŠ‚å•æ ¸RNAæµ‹åºçš„å¯ç¤º</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE226102" target="_blank" rel="noopener noreferrer">GSE226102 åŸºäºUPRmté€”å¾„çš„SHPå¯¹è–„å£³æ€§çŠ¶çš„è°ƒæ§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225960" target="_blank" rel="noopener noreferrer">GSE225960 çº¿ç²’ä½“åº”æ¿€è¯±å¯¼çš„ç³»ç»Ÿæ€§è·å¾—æ€§é€‚åº”ï¼ˆRNA-Seqï¼‰</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-28 21:39</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>